BHCM
DMRA

Brevan Howard Capital Management’s Damora Therapeutics DMRA Stock Holding History

Brevan Howard Capital Management’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-55,232
Closed -$1.43M – 2257
2026
Q1 		$1.43M Buy
+55,232
New +$1.42M 0.01% 717

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Brevan Howard Capital Management's DMRA Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Damora Therapeutics (DMRA) in Q2 2026, closing a stake of 55,232 shares — an estimated $1.43M sold.

Brevan Howard Capital Management first reported a position in DMRA in Q1 2026 and held it in 1 quarter. The position peaked at $1.43M in Q1 2026. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Damora Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 55,232 Damora Therapeutics shares in Q2 2026, an estimated $1.43M.
  • Brevan Howard Capital Management first reported a position in Damora Therapeutics in Q1 2026 and held it in 1 quarter.
  • Brevan Howard Capital Management's Damora Therapeutics position peaked at $1.43M in Q1 2026.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.